146 related articles for article (PubMed ID: 23867511)
1. Angiopoietins and non-vascular endothelial growth factor antiangiogenic targets in advanced renal cell carcinoma.
Richey SL; Hutson TE
Cancer J; 2013; 19(4):307-10. PubMed ID: 23867511
[TBL] [Abstract][Full Text] [Related]
2. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
Tang PA; Vickers MM; Heng DY
Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
[TBL] [Abstract][Full Text] [Related]
3. Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis.
Ebbinghaus SW; Gordon MS
Hematol Oncol Clin North Am; 2004 Oct; 18(5):1143-59, ix-x. PubMed ID: 15474339
[TBL] [Abstract][Full Text] [Related]
4. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
5. [Molecular tumor board-renal cell carcinoma].
Grünwald V; Doehn C; Goebell PJ
Urologe A; 2019 Jul; 58(7):768-773. PubMed ID: 31175376
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy in metastatic renal cell cancer.
Ravaud A; Gross-Goupil M; Bellmunt J
Semin Oncol; 2013 Aug; 40(4):472-81. PubMed ID: 23972711
[TBL] [Abstract][Full Text] [Related]
7. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
8. Beyond bevacizumab: antiangiogenic agents.
Rogosin S; Sandler AB
Clin Lung Cancer; 2012 Sep; 13(5):326-33. PubMed ID: 22297207
[TBL] [Abstract][Full Text] [Related]
9. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.
Sonpavde G; Willey CD; Sudarshan S
Expert Opin Investig Drugs; 2014 Mar; 23(3):305-15. PubMed ID: 24387233
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis inhibition in non-clear cell renal cancer.
Stadler W
Clin Adv Hematol Oncol; 2008 Jul; 6(7):507-9. PubMed ID: 18654117
[No Abstract] [Full Text] [Related]
12. [New targets and drugs for treatment of advanced renal cell carcinoma].
Rohde D
Aktuelle Urol; 2005 Apr; 36(2):125-30. PubMed ID: 15902572
[TBL] [Abstract][Full Text] [Related]
13. Current overview of angiogenesis inhibitors.
Ellis LM
Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
[No Abstract] [Full Text] [Related]
14. Resistance to angiogenesis inhibitors in renal cell carcinoma.
Tamaskar I; Dhillon J; Pili R
Clin Adv Hematol Oncol; 2011 Feb; 9(2):101-10. PubMed ID: 22173604
[TBL] [Abstract][Full Text] [Related]
15. Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma.
Edeline J; Mottier S; Vigneau C; Jouan F; Perrin C; Zerrouki S; Fergelot P; Patard JJ; Rioux-Leclercq N
Hum Pathol; 2012 Nov; 43(11):1982-90. PubMed ID: 22626276
[TBL] [Abstract][Full Text] [Related]
16. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.
Saylor PJ; Escudier B; Michaelson MD
Clin Genitourin Cancer; 2012 Jun; 10(2):77-83. PubMed ID: 22382009
[TBL] [Abstract][Full Text] [Related]
17. Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.
Hutson TE; Sonpavde G; Galsky MD
Clin Genitourin Cancer; 2006 Dec; 5 Suppl 1():S31-9. PubMed ID: 17239282
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Albiges L; Salem M; Rini B; Escudier B
Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
[TBL] [Abstract][Full Text] [Related]
19. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
20. Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new.
Furge KA; MacKeigan JP; Teh BT
Lancet Oncol; 2010 Jun; 11(6):571-8. PubMed ID: 20381423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
